functional-precision-medicine
(2)
Chris Apfel Is Building a Second Opinion for the Tumor Itself
The physician-scientist behind a globally used clinical score is now betting that live tumor evidence can make cancer treatment decisions less abstract, one microtumor at a time.
Sungwon Lim
Dr. Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., a Palo Alto-based precision oncology company that combines live cancer cell testing with AI to predict which drugs will work best for an individual patient's cancer - before treatment begins. Having raised $23M in Series A funding led by SoftBank Ventures Asia, ImpriMed has helped treat over 6,500 dogs with blood cancers across 130+ specialty hospitals in the US, Canada, England, and France, while publishing clinical data showing AI predictions tripled survival rates in relapsed B-cell lymphoma. A Stanford-trained bioengineer inspired by the potential of one powerful medicine to save millions, Lim pioneered a pivot into veterinary oncology as a proving ground before expanding the platform to human cancer treatment.